CLSD

Clearside Biomedical, Inc.

1.27 USD
+0.02 (+1.60%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Clearside Biomedical, Inc. stock is down -0.78% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 8 June’s closed higher than May.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprchoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX and CLS-301, an integrin inhibitor suspension for macular degeneration.